Health Care · Hospital & Medical Service Plans

CLOV CLOVER HEALTH INVESTMENTS, CORP. /DE SEC Filings & Insider Trading Activity 2026

company
CIK 1801170140 filings
Russell 2000

CLOV at a glance

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV, SEC CIK 1801170) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) reported revenue of $1.9 billion (up 40.3% from FY2024) and a net loss of $85.5 million.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) shares worth $453.5 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by THORNTON JOSEPH CLAY on November 16, 2026 of 22,099 shares at $4.97 per share.
  • In the last 90 days, CLOV insiders reported 0 open-market purchases ($0) and 17 open-market sales ($3.8M) on Form 4, a net sale of $3.8M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$1.9B
+40.3% vs prior year
Insiders · 90 days
0 buys · 17 sells
Net −$3.8M
13F holders
27 funds
$453.5M · −3 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $759.3M, up 52.9% YoY, driven by 46% membership growth and 7% higher per-member premiums
  • Net income $6.4M vs $24.4M loss YoY, adjusted EBITDA $16.1M vs $2.1M
  • Insurance segment: premiums $748.8M, benefits expense ratio 91.1% vs 93.5% YoY
  • Cash, equivalents and investments $512.6M vs $319.9M at December 31, 2025
  • Operating cash flow $203.5M vs $1.2M YoY, with $73.1M investment purchases and $5.7M financing outflow

Risk Factors

  • No material changes in risk factors from the 2025 Form 10-K
  • Carried-forward risk: adverse events could materially harm business, financial condition, and results
  • Market risk: risk events could cause Class A common stock price declines, potentially permanent
  • Regulatory disclosure risk: future SEC filings may update currently disclosed risk factors

AI summary of the CLOV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Supplemental Q&A published following Clover Health’s third-quarter 2026 earnings announcement
  • Responses address selected shareholder-submitted questions and provide additional investor context

Item EX-99.1: Item EX-99.1

  • Management sees meaningful earnings leverage through 2028 as 2025-2026 cohorts, roughly half of membership, mature into stronger economics
  • 3Q26 membership reached ~159k, leaving fixed-cost absorption potential and a stated 100-150 basis-point 2026 Adjusted SG&A improvement target
Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results announcement for quarter ended September 30, 2026
  • Full financial results and management commentary available in Exhibit 99.1

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Permanent CFO appointment effective November 4, 2026, ending interim status since March 30, 2026
  • Thornton compensation: $450,000 base salary, bonus target up to 75% of base salary

Item EX-99.1: Item EX-99.1

  • Q3 GAAP net income $6.4M, versus $(24.4)M loss, bringing nine-month profit to $61.8M
  • Revenue $759.3M, up 52.9%, with Medicare Advantage membership up 46.3% to 158,383
Filed Oct 9, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • 2027 CMS Star Ratings: 5 Stars for Clover’s PPO MA plans and 4.5 Stars for its HMO plan
  • Ratings affect payment year 2028, supporting future Medicare Advantage reimbursement

Item EX-99.1: Item EX-99.1

  • CMS awarded Clover’s PPO MA plans 5 Stars and HMO plan 4.5 Stars for 2027, affecting payment year 2028
  • 5-Star PPO status enables year-round enrollment, supporting membership growth and improved acquisition flexibility

AI summaries of CLOV 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CLOV

Don't miss the next CLOV filing

  • Alerts as it files. A push when CLOV files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CLOV, by share count.
  • Ask anything. An AI agent that reads every CLOV filing and answers with sources.

CLOV alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
THORNTON JOSEPH CLAYSellNov 16, 2026$4.97
THORNTON JOSEPH CLAYANov 4, 2026-
OLDAKOWSKI JOSEPH FRANKANov 4, 2026-
Soares KarenSellOct 20, 2026$4.66
Reynoso Jamie L.SellOct 19, 2026$4.41
Soares KarenSellOct 15, 2026$4.68
THORNTON JOSEPH CLAYSellOct 15, 2026$4.68
Wai ConradSellOct 15, 2026$4.68

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$1.4B$1.9B
Operating Income--$45.7M-$85.5M
Net Income-$213.4M-$43.0M-$85.5M
Op. Margin--3.3%-4.4%
Net Margin--3.1%-4.4%
Balance Sheet
Total Assets$570.7M$580.7M$541.0M
Equity$286.4M$341.1M$308.7M
ROE-74.5%-12.6%-27.7%
Per Share
EPS$-0.44--
Cash Flow
Operating CF-$115.9M$34.8M-$66.9M
CapEx$584K$1.6M$2.0M

Source: XBRL data in CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CLOV share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CLOV shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$453.5M
Q2 202630$497.9M
Q1 202629$153.8M
Q4 202526$218.0M
Q3 202530$283.0M
Q2 202528$283.9M
Q1 202520$205.4M
Q4 202416$142.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 206 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CLOV filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 17, 2026--
8-KNov 16, 2026Analysis-
4Nov 6, 2026--
4Nov 6, 2026--
10-QNov 6, 2026Analysis
8-KNov 4, 2026Analysis-
4Oct 20, 2026--
4Oct 20, 2026--
4Oct 19, 2026--
4Oct 19, 2026--
4Oct 19, 2026--
4Oct 19, 2026--
4Oct 19, 2026--
8-KOct 9, 2026Analysis-
4Oct 7, 2026--
4Oct 5, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
8-KSep 25, 2026Analysis-
8-KSep 24, 2026Analysis-
4Sep 18, 2026--
4Sep 17, 2026--
4Sep 16, 2026--
4Sep 15, 2026--

Related Health Care companies

All Health Care →

CLOV SEC filings: frequently asked questions

Are CLOV insiders buying or selling?

In the last 90 days, CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) officers, directors and 10% owners reported no open-market purchases and 17 open-market sales worth $3.8 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CLOV stock?

As of September 30, 2026, the largest CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) holders among the 13F filers tracked by SignalX were BlackRock ($157.4 million), Vanguard Capital Management LLC ($79.2 million), State Street Corp ($46.1 million), Vanguard Portfolio Management LLC ($32.7 million), Renaissance Technologies LLC ($19.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CLOV's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) reported revenue of $1.9 billion (up 40.3% from FY2024) and a net loss of $85.5 million. The figures come from the XBRL data in the 10-K.

What did CLOV report in its latest 8-K?

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure). Supplemental Q&A published following Clover Health’s third-quarter 2026 earnings announcement.

What are the latest CLOV SEC filings?

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 17, 2026.

What is CLOV's SEC CIK number?

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)'s SEC Central Index Key (CIK) is 1801170. EDGAR lists every CLOV filing under that number.

Ask anything about CLOV

The research agent reads CLOV's filings, financials, insider trades and 13F holders, then answers with sources.